These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 20006888

  • 1. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A.
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [Abstract] [Full Text] [Related]

  • 2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [Abstract] [Full Text] [Related]

  • 3. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [Abstract] [Full Text] [Related]

  • 4. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y, Loblaw A, Klotz L.
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [Abstract] [Full Text] [Related]

  • 5. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC, SEARCH Database Study Group.
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [Abstract] [Full Text] [Related]

  • 6. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H.
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [Abstract] [Full Text] [Related]

  • 7. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E.
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [Abstract] [Full Text] [Related]

  • 8. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
    Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ.
    J Urol; 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PubMed ID: 17085127
    [Abstract] [Full Text] [Related]

  • 9. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC.
    Cancer; 2003 Dec 01; 98(11):2344-50. PubMed ID: 14635068
    [Abstract] [Full Text] [Related]

  • 10. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.
    BJU Int; 2013 May 01; 111(6):914-20. PubMed ID: 23320782
    [Abstract] [Full Text] [Related]

  • 11. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.
    J Urol; 2007 Nov 01; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [Abstract] [Full Text] [Related]

  • 12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Nov 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 13. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ.
    J Urol; 2005 Dec 01; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC.
    J Urol; 2004 Apr 01; 171(4):1492-9. PubMed ID: 15017206
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
    Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I.
    J Urol; 2010 Sep 01; 184(3):925-9. PubMed ID: 20643452
    [Abstract] [Full Text] [Related]

  • 18. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb 01; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 19. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States.
    Pavlovich CP, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM.
    J Urol; 2008 Mar 01; 179(3):917-21; discussion 921-2. PubMed ID: 18207191
    [Abstract] [Full Text] [Related]

  • 20. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ.
    J Urol; 2003 Nov 01; 170(5):1860-3. PubMed ID: 14532793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.